谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate Coronavirus Disease 2019: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron

Michael G. Ison,Myra Popejoy,Nikolay Evgeniev,Maria Tzekova,Kathryn Mahoney,Natalia Betancourt,Yong Li,Deepali Gupta,Kristin Narayan,Ellie Hershberger,Lynn E. Connolly,Ilker Yalcin,Anita F. Das, John Genge,Michelle Smith,Ed Campanaro,Pamela Hawn,Pete Schmidt, Heloisa Costa Ravagnani Muniz

Open forum infectious diseases（2023）

引用 2|浏览4
暂无评分
关键词
adintrevimab,COVID-19,monoclonal antibody,SARS-CoV-2,treatment
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要